Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5115517 | 0.91 | KCNH2 (0.43) | KCNH2LMNAGAAALDH1A1NPSR1 | |
| SCHEMBL2484521 | 0.91 | KCNH2 (0.40) | KCNH2LMNAGAAADAMTS4MMP2 | |
| SCHEMBL7735405 | 0.85 | DAO (0.41) | LMNAALDH1A1DAOMAOBTSHR | |
| SCHEMBL20573232 | 0.85 | MAOB (0.40) | LMNAALDH1A1DAOMAOBTSHR | |
| SCHEMBL17797595 | 0.84 | LMNA (0.38) | KCNH2LMNAGAAALDH1A1HRH3 | |
| SCHEMBL22123904 | 0.84 | LMNA (0.47) | KCNH2LMNAGAANPSR1CA1 | |
| SCHEMBL12453115 | 0.84 | DAO (0.43) | LMNAMMP2ALDH1A1NPSR1DAO | |
| SCHEMBL23387596 | 0.84 | L3MBTL1 (0.47) | LMNAGAAALDH1A1NPSR1CA1 | |
| SCHEMBL23387581 | 0.82 | GPR84 (0.37) | ALDH1A1NPSR1MAOB | |
| SCHEMBL8945004 | 0.81 | MAOB (0.43) | LMNAALDH1A1HRH3MAOBCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-03-12 | — | — | US | disclosed |
| EP-2820005-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013128378-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | Piramal Enterprises Limited (IN) | 2013-09-06 | — | — | WO | disclosed |
| US-7875639-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | ABBVIE INC. | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072969-A1 | PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS | GPR55, GPR65, GPR35 | KCNH2 2515/4885LMNA 3309/4885GAA 1749/4885 |
| US-20080064699-A1 | Such as N-[3-(2-methoxyethyl)-1,3-thiazol-2(3H)-ylidene]adamantane-1-carboxamide; neuropathic, nociceptive and/or inflammatory pain; neuroprotection | OPRL1, OPRK1, OPRD1 | KCNH2 644/4885LMNA 1664/4885GAA 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.